急性心不全治療ガイドライン（2011年改訂版）
Guidelines for Treatment of Acute Heart Failure（ JCS 2011）
Guidelines for Treatment of Acute Heart Failure（ JCS 2011）
101. Singh SN, et al., for the survival trial of antiarrhythmic therapy in congestive heart failure. Amiodarone in patients with congestive heart failure and
asymptomatic ventricular arrhythmia. N Engl J Med 1995; 333: 77-82.
102. Bardy GH, et al., for the sudden cardiac death in heart failure trial (SCD-HeFT) investigators. Amiodarone or an implantable cardioverter-defibrillator
for congestive heart failure. N Engl J Med 2005; 352: 225-237.
103. Massie BM, O’Connor CM, Metra M, et al. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010; 363: 1419-
2828.
104. Teerlink JR, Metra M, Felker GM, et al. Relaxin for the treatment of patients with acute heart failure (Pre-RELAXAHF): a multicenter, randomized,
placebo-controlled, parallel-group, dose-finding phase IIb study. Lancet 2009; 373: 1429-1439.
105. Shah SJ, Blair JE, Filippatos GS, et al. Effects of Istraxime on diastolic stiffness in acute heart failure syndromes: results f rom the Hemodynami
c Echoc a rdiogr aphi c , and Neurohormonal Effects of Istraxime, a Novel Intravenous Inotropic and Lusitropic Agent: a Randomized Controlled
Trial in Patients Hospitalized with Heart Failure (HORIZONHF) trial. Am Heart J 2009; 157: 1035-1041.
106. Davis ME, Pemberton CJ, Yandle TG, et al. Urocortin 2 infusion in human heart failure. Eur Heart J 2007; 28: 2589- 2597.
107. Lapp H, Mitrovic V, Franz N, et al. Cinciguat (BAY 58- 2667) improves cardiopulmonary hemodynamics in patients with acute decompensated heart
failure. Circulation 2009; 119: 2781-2788.
108. Mebazaa A, Gheorghiade M, Piña IL, et al. Practical recommendations for prehospital and early in-hospital managements of patients presenting with
acute heart failure syndromes. Crit Care Med 2008; 36 (1 Suppl): S129-139.
109. Neumar RW, Otto CW, Link MS, et al. Part 8: Adult Advanced Cardiovascular Life Support: 2010 American Heart Association Guidelines for
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S729-767.
110. Aoyama N, Izumi T, Hiramori K, et al. Japanese Investigators of Fulminant Myocarditis: National survey of fulminant myocarditis in Japan: therapeutic
guidelines and long-term prognosis of using percutaneous cardiopulmonary support for fulminant myocarditis (special report from a
scientific committee). Circ J 2002; 66: 133-144.
111. Highlights of the 2010 American Heart Association Guideline for CPR and ECC. http://eccjapanheart.org/pdf/ ECC_Guidelines_Highlights_2010.pdf
112. Guyton AC, Lindsey AW. Effect of elevated left atrial pressure and decreased plasma protein concentration on the development of pulmonary edema.
Circ Res 1959; 7: 649- 657.
113. Masip J, Betbese AJ, Paez J, et al. Non-invasive pressure support ventilation versus conventional oxygen therapy in acute cardiogenic pulmonary
oedema: a randomized trial. Lancet 2000; 356: 2126-2132.
114. Bersten AD, Holt AW, Vedig AE, et al. Treatment of severe cardiogenic pulmonary edema with continuous positive airway pressure delivered by face
mask. N Engl J Med 1991; 325: 1825-1830.
115. Takeda S, Nejima J, Takano T, et al. Effect of nasal continuous positive airway pressure on pulmonary edema complicating acute myocardial
infarction. Jpn Circ J 1998; 62: 553-558.
116. Vital FMR, Saconato H, Ladeira MT, et al. Non-invasive positive pressure ventilation (CPAP or bilevel NPPV) for cardiogenic pulmonary edema.
Cochrane Database Syst Rev 2008; 16: CD005351. pub2.
117. Takano T, Endo T, Tanaka K, et al. Effects of positive endexpiratory pressure ventilation and extracorporeal ultrafiltration method in patients with
refractory heart failure. Jpn Circ J 1986; 50: 359-367.
118. MacIntyre NR, Cook DJ, Ely EW Jr, et al.; American College of Chest Physicians; American Association for Respiratory Care; American College of
Critical Care Medicine. Evidence-based guidelines for weaning and discontinuing ventilatory support: a collective task force facilitated by the American
College of Chest Physicians; the American Association for Respiratory Care; and the American College of Critical Care Medicine. Chest 2001; 120 (6
uppl): 375S-95S.
119. Hunt SA, Abraham WT, Chin MH, et al.; American College of Cardiology Foundation; American Heart Association. 2009 Focused update incorporated
into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults a Report of the American College of Cardiology
Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration with the International Society for Heart and
Lung Transplantation. J Am Coll Cardiol 2009; 53: e1-90.
120. Norman JC, Cooley DA, Igo SR, et al. Prognostic indices for survival during postcardiotomy intra-aortic balloon pumping. Methods of scoring and
classification, with implications for left ventricular assist device utilization. J Thorac Cardiovasc Surg 1977; 74: 709-720.
121. Antman EM, Hand M, Armstrong PW, et al. 2007 focused update of the ACC/AHA 2004 Guidel ines for the Management of Patients With ST-
Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice
Guidelines (Writing Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation
Myocardial Infarction). J Am Coll Cardiol 2008; 51: 210-247.
122. Soran O, Kennard ED, Kfoury AG, et al. Two-Year Clinical Outcomes After Enhanced External Counterpulsation (EECP) Therapy in Patients with
Refractory Angina Pectoris and Left Ventricular Dysfunction (Report from the International EECP Patient Registry). Am J Cardiol 2006; 97: 17-20.
123. 御領慎輔，高山秀和，梶川洋志，他．PCPSにおけるアルガトロバンの使用経験について．体外循環技術．2007；34：320-320.
124. Rao V, Oz MC, Flannery MA, et al. Revised screening scale to predict survival after insertion of a left ventricular assist device. J Thorac Cardiovasc
Surg 2003; 125: 855-862.
125. Lietz K, Long JW, Kfoury AG, et al. Outcomes of left ventricular assist device implantation as destination therapy in the post-REMATCH era:
implications for patient selection. Circulation 2007; 116: 497-505.
126. Levy WC, Mozaffarian D, Linker DT, et al. Can the Seattle heart failure model be used to risk-stratify heart failure patients for potential left ventricular
assist device therapy? J Heart Lung Transplant 2009; 28: 231-236.
127. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part I: inotropic infusions during hospitalization.
Circulation 2003; 108: 367-372.
128. Stevenson LW. Clinical use of inotropic therapy for heart failure: looking backward or forward? Part II: chronic inotropic therapy. Circulation 2003; 108:
492-497.
129. Dang NC, Topkara VK, Mercando M, et al. Right heart failure after left ventricular assist device implantation in patients with chronic congestive heart
failure. J Heart Lung Transplant 2006; 25: 1-6.
130. Patel ND, Weiss ES, Schaffer J, et al. Right heart dysfunction after left ventricular assist device implantation: a comparison of the pulsatile
HeartMate I and axial-flow HeartMate II devices. Ann Thorac Surg 2008; 86: 832-840.
131. Matthews JC, Koelling TM, Pagani FD, et al. The right ventricular failure risk score a pre-operative tool for assessing the risk of right ventricular failure
in left ventricular assist device candidates. J Am Coll Cardiol 2008; 51: 2163-2172.
132. Fitzpatrick JR, 3rd, Frederick JR, Hsu VM, et al. Risk score derived from pre-operative data analysis predicts the need for biventricular mechanical
circulatory support. J Heart Lung Transplant 2008; 27: 1286-1292.
133. Westaby S, Siegenthaler M, Beyersdorf F, et al. Destination therapy with a rotary blood pump and novel power delivery. Eur J Cardiothorac Surg
2010;
37: 350-356.
134. 山嵜健二，斎藤聡，西中知博，他．次世代型補助人工心臓は心臓移植の代替治療となりうるか？Gen Thrac Cardiovasc Surg. 2008; 56: 131-133.
135. Slaughter MS, Rogers JG, Milano CA, et al. Advanced Heart Failure Treated with Continuous-Flow Left Ventricular Assist Device. N Engl J Med 2009;
361: 2241-2251.
136. Miller LW, Pagani FD, Russell SD, et al. Use of a cont inuous- f low device in pat ients awai t ing hear t transplantation. N Engl J Med 2007; 357: 885-
896.
137. Wang NC, Maggioni AP, Konstam MA, et al.; Efficacy of Vasopressin Antagonismin Heart Failure Outcome Study With Tolvaptan (EVEREST)
Investigators. Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction.
JAMA 2008; 299: 2656-2666.
138. Asabi H, Bergstrom J, First P, et al. Treatment of diureticresistant fluid retention with ultrafiltration. Act Med Scan 1978; 204: 145-149.
139. Bart BA, Boyle A, Bank AJ, et al. Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded
Patients with Decompensated Congestive heart failure (RAPID-CHF) trial. J Am Coll Cardiol 2005; 46: 2043-2046.
140. Costanzo MR, Guglin ME, Saltzberg MT, et al., for the UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized
for acute decompensated heart failure. J Am Coll Cardiol 2007; 49: 675-683.
141. Little WC, Freeman GL. Pericardial disease. Circulation 2006; 113: 1622-1632.
142. Khandaker MH, Espinosa RE, Nishimura RA, et al. Pericardial disease: diagnosis and management. Mayo Clin Proc 2010; 85: 572-593.
143. Leimgruber PP, Klopfenstein HS, Wann LS, et al. The hemodynamic derangement associated with right ventricular diastolic collapse in cardiac
tamponade: an experimental echocardiographic study. Circulation 1983; 68: 612-620.
144. Appleton CP, Hatle LK, Popp RL. Cardiac tamponade and pericardial effusion: respiratory variation in transvalvular flow velocities studied by Doppler
echocardiography. J Am Coll Cardiol 1988; 11: 1020-1030.
145. Bonow RO, Carabello BA, Chatterjee K, et al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients
with valvular heart disease: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Writing
Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease): endorsed by the Society of Cardiovascular
Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation 2008; 118: e523-661.
146. Bonow RO, Carabello BA, Kanu C, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the
American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (writing committee to revise the 1998 Guidelines
for the Management of Patients With Valvular Heart Disease): developed in collaboration with the Society of Cardiovascular Anesthesiologists:
endorsed by the Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons. Circulation 2006; 114: e84-231.
147. Vahanian A, Baumgartner H, Bax J et al. Guidelines on the management of valvular heart disease: the Task Force on the Management of Valvular
Heart Disease of the European Society of Cardiology. Eur Heart J 2007; 28: 230-268.
148. Stout KK, Verrier ED. Acute Valvular Regurgitation.Circulation 2009; 119: 3232-3241.
149. Bonow RO, Carabello BA, Chatteriee K, et al. ACC/AHA 2006 Guidelines for the Management of Patients With Valvular Heart Disease. A Report of
the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998
Guidelines for the Management of Patients With Valvular Heart Disease). JACC 2006; 48: e1-148.
150. Nienaber CA, von KY, Nicolas V, et al. The diagnosis of thoracic aortic dissection by noninvasive imaging procedures.N Engl J Med 1993; 328: 1-9.
151. Smith MD, Cassidy JM, Souther S, et al. Transesophageal echocardiography in the diagnosis of traumatic rupture of the
aorta. N Engl J Med 1995; 332: 356-362.
152. Picard MH, Davidoff R, Sleeper LA, et al. Echocardiographic predictors of survival and response to early revascularization in cardiogenic shock.
Circulation 2003; 107: 279-284.
153. Antman EM, Hand M, Armstrong PW, et al. 2007 Focused Update of the ACC/AHA 2004 Guidel ines for the Management of Patients With ST-
Elevation Myocardial Infarction: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines:
developed in collaboration With the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing
Group to Review New Evidence and Update the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial
Infarction, Writing on Behalf of the 2004 Writing Committee. Circulation 2008; 117: 296-329.
154. Eagle KA, Guyton RA, Davidoff R, et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of
Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary
Artery Bypass Graft Surgery). Circulation 2004; 110: e340-437.
155. Papas PJ, Cernaianu AC, Baldino WA, et al. Ventricular free wall rupture after myocardial infarction. Chest 1991; 99: 892-895.
156. Crenshaw BS, Granger CB, Birnbaum Y, et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect
complicating acute myocardial infarction. GUSTO-I (Global Utilization of Streptokinase and TPA for Occluded Coronary Arteries) Trial Investigators.
Circulation 2000; 101: 27-32.
157. Lavie CJ , Ger sh BJ . Mechanical and elect r ical complications of acute myocardial infarction. Mayo Clin Proc 1990; 65: 709-730.
158. Emerman CL. Treatment of the acute decompensation of heart failure: efficacy and pharmacoeconomics of early initiation of therapy in the emergency
department. RevCardiovasc Med 2003; 4: S13-20.
159. Peacock WF, Braunwald E, Abraham W, et al. National Heart, Lung, and Blood Institute working group on emergency department management of
acute heart failure: research challenges and opportunities. J Am Coll Cardiol2010; 56: 343-351.
160. Alexiou VG, Ierodiakonou V, Dimopoulos G, et al. Impact of patient position on the incidence of ventilator-associated pneumonia: a meta-analysis of
randomized controlled trials. JCrit Care 2009; 24: 515-522.
161. Muscedere J, Dodek P, Keenan S, et al. Comprehensive evidence-based clinical practice guidelines for ventilatorassociated pneumonia: prevention.
J Crit Care 2008; 23: 126-137.
162. 日本集中治療医学会 ICU機能評価委員会．人工呼吸関 連肺炎予防バンドル 2010年改訂版.
163. 循環器病の診断と治療に関するガイドライン．肺血栓塞栓症および深部静脈塞栓症の診断，治療，予防に関するガイドライン（2009年改訂版）．
http://www.j-circ.or.jp/guideline/pdf/JCS2009_andod_h.pdf
164. Baba A, Hirata G, Yokoyama F, et al. Psychiatric problems of heart transplant candidates with left ventricular assist devices. J Artif Organs 2006; 9:
203-208.
165. Sessler CN, Gosnell MS, Grap MJ, et al. The Richmond Agitation-Sedation Scale: validity and reliability in adult intensive care unit patients. Am J
Respir Crit Care. Med2002; 166: 1338-1344.
166. Setoguchi S, Stevenson LW, Schneeweiss S. Repeated hospitalizations predict mortality in the community population with heart failure. Am Heart J
2007; 154: 260-266.
167. Tsuchihashi M, Tsutsui H, Kodama K, et al. Medical and socioenvironmental predictors of hospital readmission in patients with congestive heart
failure. Am Heart J 2001; 142:E7.
168. Koelling TM, Johnson ML, Cody RJ, et al. Discharge education improves clinical outcomes in patients with chronic heart failure. Circulation 2005; 111:
179-185.
169. Paul S. Hospital discharge education for patients with heart failure: what really works and what is the evidence? Crit Care Nurse 2008; 28: 66-82.
170. Konick-McMahan J, Bixby B, McKenna C. Heart failure in older adults. Providing nursing care to improve outcomes. J Gerontol Nurs 2003; 29: 35-41.
171. Maisel AS, Peacock WF, McMullin N, et al. Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated
heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008; 52: 534-540.
172. Kato N, Ito N, Kinugawa K, et al. Validity and reliability of the Japanese version of the European Heart Failure Self-Care Behavior Scale. Eur J
Cardiovasc Nurs 2008; 7: 284-289.
173. Vaccarino V, Kasl SV, Abramson J, et al. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll
Cardiol 2001; 38: 199-205.
174. Rozzini R, Sabatini T, Frisoni GB, et al. Depression and major outcomes in older patients with heart failure. Arch Intern Med 2002; 162: 362-364.
175. Kato N, Kinugawa K, Yao A, et al. Relationship of depressive symptoms with hospitalization and death in Japanese patients with heart failure. J Card
Fail 2009; 15:912-919.
176. Tsuchihashi-Makaya M, Kato N, Chishaki A, et al. Anxiety and poor social support are independently associated with adverse outcomes in patients
with mild heart failure. Circ J 2009; 73: 280-287.
177. Hutt E, Frederickson E, Ecord M, et al. Associations among processes and outcomes of care for Medicare nursing home residents with acute heart
failure. J Am Med Dir Assoc2003; 4: 195-199.
178. Pi-Figueras M, Aguilera A, Arellano M, et al. Prevalence of deliriumin a geriatric convalescence hospitalization unit: patient’s clinical characteristics
and risk precipitating factor analysis. Arch Gerontol Geriatr 2004; 9 (Suppl): 333-337.
179. Ely EW, Shintani A, Truman B, et al. Delirium as a predictor of mortality in mechanically ventilated patients in the intensive care unit. JAMA 2004;
291: 1753-1762.
180. 稲田健．病態生理と病因．西村勝治，山内典子編．せん妄ケアを究める．重症化させないための看護．看護技術2011；57：9-16.
181. Inouye SK, Bogardus ST Jr, Charpentier PA, et al. A multicomponent intervention to prevent deliriumin hospitalized older patients. N Engl J Med 1999;
340: 669-676.
182. Cole MG, McCusker J, Bellavance F, et al. Systematic detection and multidisciplinary care of deliriumin older medical inpatients: a randomized trial.
CMAJ 2002; 167:753-759.
183. 町田いづみ．せん妄スクリーニングツール．総合病院精神医学 2002；14：1-8.
184. Neelon VJ, Champagne MT, Carlson JR, et al. The NEECHAM Confusion Scale: construction, validation, and clinical testing. Nurs Res. 1996; 45:
324-
330.
185. Ely EW, Margolin R, Francis J, et al. Evaluation of deliriumin critically ill patients: validation of the Confusion Assessment Method for the Intensive
Care Unit (CAM-ICU).Crit Care Med 2001; 29: 1370-1379.
186. 日本呼吸療法医学会．人工呼吸中の鎮静のためのガイド ライン．人工呼吸 2007；24：146-167.
187. Grady KL, Dracup K, Kennedy G, et al. Team management of patients with heart failure: A statement for healthcare professionals from The
Cardiovascular Nursing Council of the American Heart Association. Circulation 2000; 102: 2443-2456.
188. 循環器病の診断と治療に関するガイドライン．慢性心不全治療ガイドライン（2010年改訂版）．
http://www.j-circ.or.jp/guideline/pdf/JCS2009_andod_h.pdf（2010年12月閲覧）．
189. Hochman JS, Sleeper LA, Webb JG, et al.; SHOCK Investigators. Early revascularization and long-term survival in cardiogenic shock complicating
acute myocardial infarction. JAMA 2006; 295: 2511-2515.
190. Matsubara T, Minatoguchi S, Matsuo H, et al. Three minute, but not one minute, ischemia and nicorandil have a preconditioning effect in patients with
coronary artery disease. J Am Coll Cardiol 2000; 35: 345-351.
191. Iwakura K, Ito H, Okamura A, et al. Nicorandil treatment in patients with acute myocardial infarction: a meta-analysis. Circ J 2009; 73: 925-931. Epub
2009 Mar 27.
192. Asakura M, Kitakaze M. Cardioprotection in the clinical setting-lessons from J-WIND studies. Cardiovasc Drugs Ther 2010; 24: 289-295.
193. Ki takaze M, Asakura M, Kim J , et al . ; J -WIND investigators. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment
for
acute myocardial infarction (J-WIND): two randomized trials. Lancet 2007; 370: 1483-1493. Erratumin: Lancet. 2008; 370: 2102.
194. Ivanes F, Mewton N, Rioufol G, et al. Cardioprotection in the clinical setting. Cardiovasc Drugs Ther 2010; 24: 281- 287. Review.
195. Ricci R, Coletta C, Ceci V, et al.; RIMA Researchers. Effect of early treatment with captopril and metoprolol singly and together on postinfarction left
ventricular remodeling. Am Heart J 2001; 142: E5.
196. Califf RM, Lokhnygina Y, Velazquez EJ, et al. Usefulness of beta blockers in high-risk patients after myocardial infarction in conjunction with captopril
and/or valsartan (from the Valsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol 2009; 104: 151-157.
197. Khan MG. Complication of myocardial infarction and postinfarction care. In Heart Disease Diagnosis and Therapy (Khan MG, Marriott HJL, et al. Ed).
Williams & Wilkins, Baltimore 1996: 61-74.
198. 循環器病の診断と治療に関するガイドライン．急性心筋梗塞（ST上昇型）の診療に関するガイドライン．Circ J2008；72，Suppl．IV：1348-1442.
199. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. The
Cardiac Arrhythmia Suppression Trial (CAST) Investigators. N Engl J Med 1989; 321: 406-412.
200. Figueras J, Calvo F, Cortadellas J, Soler-Soler J. Comparison of patients with and without papillary muscle rupture during acute myocardial infarction.
Am J Cardiol 1997; 80: 625-627.